ABVC BioPharma’s Vitreous Substitute Vitargus Presented at 14th APVRS Congress
December 22, 2021 08:30 ET
|
ABVC BioPharma, Inc.
Fremont, CA, Dec. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award
December 15, 2021 08:30 ET
|
ABVC BioPharma, Inc.
Fremont, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement
December 09, 2021 08:30 ET
|
ABVC BioPharma, Inc.
Fremont, CA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results
November 15, 2021 16:33 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that deliver high efficacy...
ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M
November 11, 2021 09:00 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc.(Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that deliver high efficacy...
Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites
October 27, 2021 08:30 ET
|
ABVC BioPharma, Inc.
ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study Completion of the Study Expected by the End of 2022 FREMONT, CA, Oct. 27, 2021 (GLOBE...
ABVC BioPharma Restructures Joint Venture to Expand Access to Early-Stage Research
October 12, 2021 08:30 ET
|
ABVC BioPharma, Inc.
Restructured Venture Also Seeks Licensing Partners for ABVC FREMONT, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical...
ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study
September 13, 2021 08:30 ET
|
ABVC BioPharma, Inc.
Completion of the Study Expected by the End of 2022 FREMONT, CA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments
September 01, 2021 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Report Updated by Zacks/SCR
August 30, 2021 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...